Sunday, July 10, 2005

Amgen's official statement on halting GDNF study for Parkinson's

On the one hand, this is exactly what you'd want a drug company to do as soon as indications came up from studies that there may be a fatal safety issue with a drug.

On the other hand, it's a very sad situation, especially tragic for the people who personally feel that they are willing to take the risks with fully informed consent, both for themselves and for hopes of developing a treatment for Parkinson's disease.

No comments:

Post a Comment